 Pharmaceutical Preparations
"Pharmaceutical Preparations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.
| Descriptor ID |
D004364
|
| MeSH Number(s) |
D26
|
| Concept/Terms |
Pharmaceutical Preparations- Pharmaceutical Preparations
- Preparations, Pharmaceutical
- Pharmaceutical Products
- Products, Pharmaceutical
- Drugs
- Pharmaceutic Preparations
- Preparations, Pharmaceutic
|
Below are MeSH descriptors whose meaning is more general than "Pharmaceutical Preparations".
Below are MeSH descriptors whose meaning is more specific than "Pharmaceutical Preparations".
This graph shows the total number of publications written about "Pharmaceutical Preparations" by people in UAMS Profiles by year, and whether "Pharmaceutical Preparations" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2019 | 1 | 0 | 1 | | 2018 | 1 | 2 | 3 | | 2017 | 2 | 0 | 2 | | 2016 | 2 | 1 | 3 | | 2015 | 2 | 2 | 4 | | 2014 | 1 | 0 | 1 | | 2013 | 4 | 2 | 6 | | 2012 | 1 | 1 | 2 | | 2011 | 2 | 2 | 4 | | 2010 | 2 | 1 | 3 | | 2008 | 3 | 1 | 4 | | 2007 | 1 | 0 | 1 | | 2006 | 3 | 0 | 3 | | 2005 | 1 | 0 | 1 | | 2003 | 4 | 1 | 5 | | 2000 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 1996 | 0 | 3 | 3 | | 1995 | 0 | 1 | 1 | | 1993 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pharmaceutical Preparations" by people in Profiles over the past ten years.
-
Kennon-McGill S, Clemens MM, McGill MR. Expression of drug metabolizing enzymes and transporters in the cochlea: Implications for drug delivery and ototoxicity. Hear Res. 2019 08; 379:98-102.
-
van den Anker J, Reed MD, Allegaert K, Kearns GL. Developmental Changes in Pharmacokinetics and Pharmacodynamics. J Clin Pharmacol. 2018 10; 58 Suppl 10:S10-S25.
-
Khojasteh SC, Miller GP, Mitra K, Rietjens IMCM. Biotransformation and bioactivation reactions - 2017 literature highlights *. Drug Metab Rev. 2018 08; 50(3):221-255.
-
George N, Chen M, Yuen N, Hunt CM, Suzuki A. Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. Regul Toxicol Pharmacol. 2018 Apr; 94:101-107.
-
Hirashima R, Itoh T, Tukey RH, Fujiwara R. Prediction of drug-induced liver injury using keratinocytes. J Appl Toxicol. 2017 07; 37(7):863-872.
-
Zharov VP, Latyshev AS. Laser Non-Contact Drug Delivery Methods: Mathematical and Experimental Substantiation. Crit Rev Biomed Eng. 2017; 45(1-6):303-317.
-
Jones SM, Chowdhury ZK, Watts MJ. A taxonomy of chemicals of emerging concern based on observed fate at water resource recovery facilities. Chemosphere. 2017 Mar; 170:153-160.
-
Hanna J, Bian J, Hogan WR. An accurate and precise representation of drug ingredients. J Biomed Semantics. 2016; 7:7.
-
Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 2016 Apr; 21(4):648-53.
-
Zhang J, Doshi U, Suzuki A, Chang CW, Borlak J, Li AP, Tong W. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles. Chem Biol Interact. 2016 Aug 05; 255:3-11.
-
Nedosekin DA, Foster S, Nima ZA, Biris AS, Galanzha EI, Zharov VP. Photothermal confocal multicolor microscopy of nanoparticles and nanodrugs in live cells. Drug Metab Rev. 2015 08; 47(3):346-55.
-
Djoussé L, Petrone AB, Blackshear C, Griswold M, Harman JL, Clark CR, Talegawkar S, Hickson DA, Gaziano JM, Dubbert PM, Correa A, Tucker KL, Taylor HA. Prevalence and changes over time of ideal cardiovascular health metrics among African-Americans: the Jackson Heart Study. Prev Med. 2015 May; 74:111-6.
-
Bajcetic M, Kearns GL, Jovanovic I, Brajovic M, van den Anker JN. Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA. Curr Pharm Des. 2015; 21(39):5668-73.
-
Abdel-Rahman SM, Ridge A, Kearns GL. Estimation of body weight in children in the absence of scales: a necessary measurement to insure accurate drug dosing. Arch Dis Child. 2014 Jun; 99(6):570-4.
-
James LP. Metabolomics: integration of a new "omics" with clinical pharmacology. Clin Pharmacol Ther. 2013 Nov; 94(5):547-51.
-
Jambhekar SS, Breen PJ. Drug dissolution: significance of physicochemical properties and physiological conditions. Drug Discov Today. 2013 Dec; 18(23-24):1173-84.
-
Kim J, Xi J, Si X, Berlinski A, Su WC. Hood nebulization: effects of head direction and breathing mode on particle inhalability and deposition in a 7-month-old infant model. J Aerosol Med Pulm Drug Deliv. 2014 Jun; 27(3):209-18.
-
Yang L, Price ET, Chang CW, Li Y, Huang Y, Guo LW, Guo Y, Kaput J, Shi L, Ning B. Gene expression variability in human hepatic drug metabolizing enzymes and transporters. PLoS One. 2013; 8(4):e60368.
-
Pogribny IP, Beland FA. Role of microRNAs in the regulation of drug metabolism and disposition genes in diabetes and liver disease. Expert Opin Drug Metab Toxicol. 2013 Jun; 9(6):713-24.
-
Kodell RL, Chen JJ. Quantitative benefit-risk analysis for evaluating drug therapies. J Biopharm Stat. 2013; 23(1):231-8.
-
Howell BA, Yang Y, Kumar R, Woodhead JL, Harrill AH, Clewell HJ, Andersen ME, Siler SQ, Watkins PB. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn. 2012 Oct; 39(5):527-41.
-
Melchert RB, Fincham JE. Escalating medication shortages: a public health and patient care crisis. Mo Med. 2012 Jan-Feb; 109(1):20-3.
-
Laughon MM, Benjamin DK, Capparelli EV, Kearns GL, Berezny K, Paul IM, Wade K, Barrett J, Smith PB, Cohen-Wolkowiez M. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol. 2011 Sep; 4(5):643-52.
-
Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol. 2011 Sep 19; 24(9):1345-410.
-
Nelson RE, McAdam-Marx C, Evans ML, Ward R, Campbell B, Brixner D, Lafleur J. Patent extension policy for paediatric indications: an evaluation of the impact within three drug classes in a state Medicaid programme. Appl Health Econ Health Policy. 2011 May 01; 9(3):171-81.
-
Neville KA, Becker ML, Goldman JL, Kearns GL. Developmental pharmacogenomics. Paediatr Anaesth. 2011 Mar; 21(3):255-65.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|